Advocacy intelligence hub — real-time data for patient organizations
Sheba Medical Center — PHASE1, PHASE2
Octant, Inc. — PHASE1, PHASE2
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — EARLY_PHASE1
Zhongshan Ophthalmic Center, Sun Yat-sen University — PHASE3
PYC Therapeutics — PHASE1, PHASE2
University of Rochester — PHASE1
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — PHASE1
University Medical Center Goettingen
Ocugen — PHASE3
PYC Therapeutics — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
LUXTURNA
(voretigene neparvovec-rzyl)Orphan drugstandardSpark Therapeutics, Inc.
12.1 Mechanism of Action LUXTURNA is designed to deliver a normal copy of the gene encoding the human retinoid isomerohydrolase RPE65 (RPE65) to cells...